<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Specific inhibitors of cyclooxygenase 2 (COX-2) have been approved for the treatment of <z:hpo ids='HP_0002758'>osteoarthritis</z:hpo> and <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Unlike <z:chebi fb="2" ids="35475">nonsteroidal anti-inflammatory drugs</z:chebi>, specific COX-2 inhibitors do not inhibit platelet activation </plain></SENT>
<SENT sid="2" pm="."><plain>However, these agents significantly reduce systemic production of prostacyclin </plain></SENT>
<SENT sid="3" pm="."><plain>As a result, theoretical concerns have been raised that specific COX-2 inhibitors could shift the hemostatic balance toward a prothrombotic state </plain></SENT>
<SENT sid="4" pm="."><plain>Patients with <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue diseases</z:e> (CTD), who may be predisposed to vasculopathy and <z:mp ids='MP_0005048'>thrombosis</z:mp>, often have <z:hpo ids='HP_0001369'>arthritis</z:hpo> or pain syndromes requiring treatment with <z:chebi fb="1" ids="35472">antiinflammatory agents</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Herein we describe 4 patients with CTD who developed ischemic complications after receiving <z:chebi fb="0" ids="41423">celecoxib</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients had a history of <z:e sem="disease" ids="C0034735" disease_type="Disease or Syndrome" abbrv="">Raynaud's phenomenon</z:e>, as well as elevated anticardiolipin antibodies, <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>, or a history compatible with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>It was possible to measure a urinary metabolite of <z:chebi fb="0" ids="15627">thromboxane A2</z:chebi> in 2 of the patients as an indicator of in vivo platelet activation, and this was markedly elevated in both </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, the patients had evidence of ongoing <z:mp ids='MP_0001845'>inflammation</z:mp> as indicated by <z:hpo ids='HP_0003565'>elevated erythrocyte sedimentation rate</z:hpo>, hypocomplementemia, and/or elevated levels of anti-DNA antibodies </plain></SENT>
<SENT sid="9" pm="."><plain>The findings in these 4 patients suggest that COX-2 inhibitor-treated patients with diseases that predispose to <z:mp ids='MP_0005048'>thrombosis</z:mp> should be monitored carefully for this complication </plain></SENT>
</text></document>